Published in Nature on June 27, 2007
Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell (2008) 14.17
MYC on the path to cancer. Cell (2012) 8.65
Myc's broad reach. Genes Dev (2008) 7.56
Role of the murine reprogramming factors in the induction of pluripotency. Cell (2009) 7.46
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 6.49
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 5.35
Epigenetic reprogramming and induced pluripotency. Development (2009) 4.90
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res (2009) 4.32
Identification of early replicating fragile sites that contribute to genome instability. Cell (2013) 3.99
MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer (2010) 3.64
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol (2009) 2.79
Genome-wide studies highlight indirect links between human replication origins and gene regulation. Proc Natl Acad Sci U S A (2008) 2.77
Drosophila ORC localizes to open chromatin and marks sites of cohesin complex loading. Genome Res (2009) 2.66
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 2.44
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers. PLoS One (2012) 2.38
Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One (2008) 2.12
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia (2011) 2.12
Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol (2009) 1.99
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A (2011) 1.90
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A (2011) 1.90
Myc proteins as therapeutic targets. Oncogene (2010) 1.88
Roles of Werner syndrome protein in protection of genome integrity. DNA Repair (Amst) (2010) 1.82
Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res (2010) 1.82
p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A (2010) 1.77
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat Rev Mol Cell Biol (2008) 1.72
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A (2010) 1.65
Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A (2012) 1.65
Redeployment of Myc and E2f1-3 drives Rb-deficient cell cycles. Nat Cell Biol (2015) 1.61
The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci U S A (2009) 1.57
Mechanisms and pathways of growth failure in primordial dwarfism. Genes Dev (2011) 1.56
Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer (2009) 1.56
An overview of MYC and its interactome. Cold Spring Harb Perspect Med (2014) 1.53
MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med (2014) 1.51
Oncogene-induced cellular senescence elicits an anti-Warburg effect. Proteomics (2013) 1.50
MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer (2015) 1.47
Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nat Rev Cancer (2012) 1.45
Replication stress and cancer. Nat Rev Cancer (2015) 1.43
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One (2008) 1.42
Institutional shared resources and translational cancer research. J Transl Med (2009) 1.41
Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol (2008) 1.41
Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover. Nat Cell Biol (2010) 1.39
Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency. Proc Natl Acad Sci U S A (2009) 1.37
Oncogenes induce genotoxic stress by mitotic processing of unusual replication intermediates. J Cell Biol (2013) 1.37
RNA-dependent recruitment of the origin recognition complex. EMBO J (2008) 1.37
Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO J (2008) 1.36
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci U S A (2009) 1.36
Interaction between HMGA1a and the origin recognition complex creates site-specific replication origins. Proc Natl Acad Sci U S A (2008) 1.36
Replication stress and cancer: it takes two to tango. Exp Cell Res (2014) 1.33
c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS One (2009) 1.32
MYC, Metabolism, and Cancer. Cancer Discov (2015) 1.29
L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci U S A (2010) 1.27
A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS One (2011) 1.27
Exosome removal as a therapeutic adjuvant in cancer. J Transl Med (2012) 1.24
Roles of the Werner syndrome RecQ helicase in DNA replication. DNA Repair (Amst) (2008) 1.20
AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med (2013) 1.19
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer (2010) 1.18
MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol (2008) 1.17
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol (2013) 1.17
A nontranscriptional role for HIF-1α as a direct inhibitor of DNA replication. Sci Signal (2013) 1.17
Cdc45 is a critical effector of myc-dependent DNA replication stress. Cell Rep (2013) 1.16
Drosophila growth and development in the absence of dMyc and dMnt. Dev Biol (2007) 1.13
Genome recognition by MYC. Cold Spring Harb Perspect Med (2014) 1.10
Insulator protein Su(Hw) recruits SAGA and Brahma complexes and constitutes part of Origin Recognition Complex-binding sites in the Drosophila genome. Nucleic Acids Res (2013) 1.10
MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin Oncol (2011) 1.09
Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. PLoS One (2010) 1.07
The TAGteam motif facilitates binding of 21 sequence-specific transcription factors in the Drosophila embryo. Genome Res (2012) 1.07
c-myc and N-myc promote active stem cell metabolism and cycling as architects of the developing brain. Oncotarget (2010) 1.07
Molecular architecture of the DNA replication origin activation checkpoint. EMBO J (2010) 1.04
Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells. Elife (2015) 1.03
New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res (2013) 1.02
Unstable spinocerebellar ataxia type 10 (ATTCT*(AGAAT) repeats are associated with aberrant replication at the ATX10 locus and replication origin-dependent expansion at an ectopic site in human cells. Mol Cell Biol (2007) 1.02
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov (2015) 1.01
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int (2013) 1.01
Myc transcription factors: key regulators behind establishment and maintenance of pluripotency. Regen Med (2010) 1.00
B-Myb is critical for proper DNA duplication during an unperturbed S phase in mouse embryonic stem cells. Stem Cells (2010) 1.00
MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res (2012) 0.99
Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1. Cell Death Differ (2012) 0.99
BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J (2013) 0.98
Why are we where we are? Understanding replication origins and initiation sites in eukaryotes using ChIP-approaches. Chromosome Res (2010) 0.98
Premetazoan ancestry of the Myc-Max network. Mol Biol Evol (2011) 0.98
MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel. PLoS One (2009) 0.98
A subset of Drosophila Myc sites remain associated with mitotic chromosomes colocalized with insulator proteins. Nat Commun (2013) 0.97
Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. Carcinogenesis (2009) 0.97
c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland. BMC Biol (2009) 0.96
Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol (2010) 0.96
IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity. J Exp Med (2013) 0.95
c-Myc suppression of DNA double-strand break repair. Neoplasia (2012) 0.95
Su(z)2 antagonizes auto-repression of Myc in Drosophila, increasing Myc levels and subsequent trans-activation. PLoS One (2009) 0.94
Cell cycle arrest by transforming growth factor beta1 near G1/S is mediated by acute abrogation of prereplication complex activation involving an Rb-MCM interaction. Mol Cell Biol (2009) 0.94
Control of vertebrate development by MYC. Cold Spring Harb Perspect Med (2013) 0.94
Global regulation of genome duplication in eukaryotes: an overview from the epifluorescence microscope. Chromosoma (2008) 0.94
RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model. Blood (2013) 0.93
Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency. Oncogene (2011) 0.93
The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells. J Cell Mol Med (2011) 0.93
Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance. Cell Div (2012) 0.93
Reverse engineering of regulatory networks in human B cells. Nat Genet (2005) 13.16
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
Modes of p53 regulation. Cell (2009) 9.31
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature (2002) 7.71
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
Double-strand break end resection and repair pathway choice. Annu Rev Genet (2011) 7.31
Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol (2008) 6.09
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol (2006) 5.70
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell (2006) 5.64
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol (2003) 5.46
SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell (2007) 5.30
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 5.23
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature (2004) 5.06
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol (2005) 4.89
SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab (2008) 4.89
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell (2005) 4.60
ATR and ATM regulate the timing of DNA replication origin firing. Nat Cell Biol (2004) 4.39
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell (2002) 4.33
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab (2005) 4.14
A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell (2004) 4.05
Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer (2004) 4.04
A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell (2007) 3.81
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol (2005) 3.75
Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A (2003) 3.45
Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst (2003) 3.44
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem (2002) 3.37
Direct activation of RNA polymerase III transcription by c-Myc. Nature (2003) 3.32
How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
Non-invasive prenatal measurement of the fetal genome. Nature (2012) 3.11
Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics (2007) 3.09
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle (2009) 3.07
A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol (2008) 3.07
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Parc: a cytoplasmic anchor for p53. Cell (2003) 3.06
Acetylation inactivates the transcriptional repressor BCL6. Nat Genet (2002) 3.00
A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol (2008) 2.99
An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol Cell (2003) 2.96
A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol (2010) 2.92
Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol (2006) 2.85
Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer (2005) 2.79
Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol (2009) 2.79
AID is required for germinal center-derived lymphomagenesis. Nat Genet (2007) 2.79
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell (2010) 2.73
Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol (2005) 2.72
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol (2005) 2.64
Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat Struct Mol Biol (2009) 2.64
SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem (2005) 2.59
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell (2012) 2.46
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol (2006) 2.35
Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood (2012) 2.30
Rad50 adenylate kinase activity regulates DNA tethering by Mre11/Rad50 complexes. Mol Cell (2007) 2.30
Nearly finished genomes produced using gel microdroplet culturing reveal substantial intraspecies genomic diversity within the human microbiome. Genome Res (2013) 2.29
Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst (2009) 2.22
Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res (2010) 2.14
PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proc Natl Acad Sci U S A (2005) 2.13
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood (2002) 2.13
Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. Nature (2008) 2.12
Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex. Nat Struct Mol Biol (2006) 2.09
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06
Regulation of DNA replication by ATR: signaling in response to DNA intermediates. DNA Repair (Amst) (2004) 2.05
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol (2010) 2.03
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell (2011) 2.01
Microfluidics for flow cytometric analysis of cells and particles. Physiol Meas (2005) 2.00
Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood (2003) 1.93
Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem (2003) 1.92
Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell (2009) 1.92
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood (2002) 1.91
A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol (2002) 1.90
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol (2012) 1.90